Top

International Urology and Nephrology

Published in:

01-10-2012 | Nephrology – Original Paper

Good response to HBsAg vaccine in dialysis patients is associated with high CD4+/CD8+ ratio

Authors: Funda Sari, Hulya Taskapan

Published in: International Urology and Nephrology | Issue 5/2012

Abstract

Objective

Chronic renal failure is accompanied by various abnormalities of innate and acquired, cellular and humoral immunity. We aimed to investigate whether positive Candida skin test results, CD4+ and CD8+, before the first dose of vaccination could be a predictor for antibody response to hepatitis B vaccination and the relation of these parameters with hepatitis B antibody levels 1 month after the last dose of vaccination.

Materials and methods

The present study was carried out in 57 dialysis patients. All patients received recombinant hepatitis B vaccine (40 μg) given intramuscularly in the deltoid muscle in a four-dose schedule at 0, 1, 2, and 6 months. Candida skin test and lymphocyte subsets (CD4+ and CD8+) were determined before the first dose of vaccination and 1 month after the fourth inoculation of hepatitis B vaccine.

Results

Ten patients (17.5%) were non-responders (HBsAb < 10 IU/L), while 47 patients (82.5%) were responders (HBsAb ≥ 10 IU/L). However, 29 patients (50.9%) were weak responders (HBsAb:10–100 IU/L), 18 patients (31.6%) good responders (HBsAb > 100 IU/L), which was determined 1 month after the fourth dose of vaccination. Thirty-nine patients (68.4%) and 44 patients (77.2%) were anergic to Candida skin test before the first dose and 1 month after fourth inoculation of hepatitis B vaccine, respectively. There was no relationship between Candida skin test and response to hepatitis B vaccination. Mean age was lower, and CD4+/CD8+ ratio measured both before and after vaccination was higher in good responders compared with that of weak responders and that of non-responders. Females were better responders than males.

Conclusion

High skin test anergy rate and low seroconversion rate after hepatitis B vaccination are important problems in patients on dialysis. Females, younger patients, and patients with higher CD4+/CD8+ ratio have better HBsAb antibody response to hepatitis B vaccination.

Griveas I, Visvardis G, Fleva A, Papadopoulou D, Mitsopoulos E, Kyriklidou P, Manou E, Ginikopoulou E, Meimaridou D, Paulitou A, Sakellariou G (2005) Comparative analysis of immunophenotypic abnormalities in cellular immunity of uremic patients undergoing either hemodialysis or continuous ambulatory peritoneal dialysis. Ren Fail 27(3):279–282PubMed

Casciani CU, De Simone C, Bonini S, Gallucci MT, Matteucci G, Valesini G, Meli D, Masala C (1978) Immunological aspects of chronic uremia. Kidney Int Suppl 8:S49–S54PubMed

Girndt M, Sester U, Sester M, Kaul H, Köhler H (1999) Impaired cellular immune function in patients with end-stage renal failure. Nephrol Dial Transplant 14(12):2807–2810PubMedCrossRef

Girndt M, Sester M, Sester U, Kaul H, Köhler H (2001) Molecular aspects of T- and B-cell function in uremia. Kidney Int Suppl 78:S206–S211PubMed

Alexiewicz JM, Smogorzewski M, Fadda GZ, Massry SG (1991) Impaired phagocytosis in dialysis patients: studies on mechanisms. Am J Nephrol 11(2):102–111PubMedCrossRef

Sester U, Sester M, Hauk M, Kaul H, Köhler H, Girndt M (2000) T-cell activation follows Th1 rather than Th2 pattern in haemodialysis patients. Nephrol Dial Transplant 15(8):1217–1223PubMedCrossRef

Beaman M, Michael J, MacLennan IC, Adu D (1989) T-cell-independent and T-cell-dependent antibody responses in patients with chronic renal failure. Nephrol Dial Transplant 4(3):216–221PubMed

Chow KM, Law MC, Leung CB, Szeto CC, Li PK (2006) Antibody response to hepatitis B vaccine in end-stage renal disease patients. Nephron Clin Pract 103(3):c89–c93PubMedCrossRef

Kara IH, Yilmaz ME, Suner A, Kadiroglu AK, Isikoglu B (2004) The evaluation of immune responses that occur after HBV infection and HBV vaccination in hemodialysis patients. Vaccine 22(29–30):3963–3967PubMedCrossRef

10.

Martin P, Friedman LS (1995) Chronic viral hepatitis and the management of chronic renal failure. Kidney Int 47(5):1231–1241PubMedCrossRef

11.

Smirnoff M, Patt C, Seckler B, Adler JJ (1998) Tuberculin and anergy skin testing of patients receiving long-term hemodialysis. Chest 113(1):25–27PubMedCrossRef

12.

Woeltje KF, Mathew A, Rothstein M, Seiler S, Fraser VJ (1998) Tuberculosis infection and anergy in hemodialysis patients. Am J Kidney Dis 31(5):848–852PubMedCrossRef

13.

Lesourd BM, Wang A, Moulias R (1985) Serial delayed cutaneous hypersensitivity skin testing with multiple recall antigens in healthy volunteers: booster effect study. Ann Allergy 55(5):729–735PubMed

14.

Taskapan H, Oymak O, Utas C (2000) Tuberculin and anergy testing in CAPD patients. Perit Dial Int 20(6):807–809PubMed

15.

Yoon JW, Gollapudi S, Pahl MV, Vaziri ND (2006) Naïve and central memory T-cell lymphopenia in end-stage renal disease. Kidney Int 70(2):371–376PubMedCrossRef

16.

Carvounis CP, Manis T, Coritsidis G, Dubinsky M, Serpente P (2000) Total lymphocyte count: a promising prognostic index of mortality in patients on CAPD. Perit Dial Int 20(1):33–38PubMed

17.

Quadracci LJ, Ringdén O, Krzymanski M (1976) The effect of uremia and transplantation on lymphocyte subpopulations. Kidney Int 10(2):179–184PubMedCrossRef

18.

Chatenoud L, Herbelin A, Beaurain G, Descamps-Latscha B (1990) Immune deficiency of the uremic patient. Adv Nephrol Necker Hosp 19:259–274PubMed

19.

Cohen G, Haag-Weber M, Hörl WH (1997) Immune dysfunction in uremia. Kidney Int Suppl 62:S79–S82PubMed

20.

Descamps-Latscha B, Chatenoud L (1996) T cells and B cells in chronic renal failure. Semin Nephrol 16(3):183–191PubMed

21.

Litjens NH, Huisman M, van den Dorpel M, Betjes MG (2008) Impaired immune responses and antigen-specific memory CD4+ T cells in hemodialysis patients. J Am Soc Nephrol 19(8):1483–1490PubMedCrossRef

22.

Liu YL, Kao MT, Huang CC (2005) A comparison of responsiveness to hepatitis B vaccination in patients on hemodialysis and peritoneal dialysis. Vaccine 23(30):3957–3960PubMedCrossRef

23.

Mauri JM, Vallès M (1997) Effects of recombinant interleukin-2 and revaccination for hepatitis B in previously vaccinated, non-responder, chronic uraemic patients. Collaborative Group of Girona. Nephrol Dial Transplant 12(4):729–732PubMedCrossRef

24.

el-Reshaid K, al-Mufti S, Johny KV, Sugathan TN (1994) Comparison of two immunization schedules with recombinant hepatitis B vaccine and natural immunity acquired by hepatitis B infection in dialysis patients. Vaccine 12(3):223–234PubMedCrossRef

25.

Sjogren MH (2005) Prevention of hepatitis B in nonresponders to initial hepatitis B virus vaccination. Am J Med 118(Suppl 10A):34S–39SPubMedCrossRef

26.

Rohman F, Dahmem A, Herzog-Houff S, Bocher WO, Gall PR, Lohr HF (2000) Cellular and humoral responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface. Heptology 31:521–527CrossRef

27.

Armstrong KE, Bush HM, Collins JD, Feola DJ, Caldwell GC, Thornton AC (2010) Role of CD4 count in immunity development after hepatitis A and B vaccination among HIV-infected patients: Kentucky, 2002–2007. J Int Assoc Physicians AIDS Care (Chic Ill) 9(3):179–186CrossRef

Title: Good response to HBsAg vaccine in dialysis patients is associated with high CD4+/CD8+ ratio
Authors: Funda Sari
Hulya Taskapan
Publication date: 01-10-2012
Publisher: Springer Netherlands
Published in: International Urology and Nephrology / Issue 5/2012
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-011-0043-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2012

Variability in CKD stage in outpatients followed in two large renal clinics: implications for CKD trials and the status of current knowledge of patterns of CKD to ESRD progression: response to Dr. Onuigbo

Extrication of penile entrapment in a polyethylene terephthalate (PET) bottle: a technique of suture traction and Dundee and literature review

Treating stress urinary incontinence in female patients with neuropathic bladder: the value of the autologous fascia rectus sling

Variability in CKD stage in outpatients followed in two large renal clinics: implications for CKD trials and the status of current knowledge of patterns of CKD to ESRD progression

Impact of a learning curve model in kidney transplantation on functional outcome and surgical complications in a small volume centre: does size really matter?

Optimized outcomes for renal allografts with cold ischemic times of 20 h or greater

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials